Ball (BALL) Q4 2025 Earnings Transcript

Ball reported record 2025 results, with comparable diluted EPS up 13% to $3.57, adjusted free cash flow rising 2.4x to $956 million, and $1.54 billion returned to shareholders. Management guided to at least 10% comparable EPS growth in 2026, free cash flow above $900 million, and at least $600 million of share repurchases, while flagging a $35 million headwind from Millersburg start-up and tariff-related costs. The recently closed Benepack acquisition should add about 1.7 billion units of capacity, but profitability contribution is expected to be minimal in 2026 and more meaningful in 2027.

Analysis

BALL is turning a capacity problem into a margin story. The key second-order effect is that near-term “headwinds” from Millersburg and Benepack are really a prelude to a step-up in pricing power and operating leverage once constrained geographies re-open; this matters because the market tends to underwrite new plants as dilutive until utilization inflects, but here the backlog of contracted demand makes the ramp unusually visible. In other words, 2026 is likely the trough year for North America earnings power and the setup for a sharper 2027 margin reset.

The more interesting bull case is not volume growth itself, but the mix of balance-sheet repair and buyback intensity. With leverage still above the stated target and repurchases continuing, every incremental dollar of FCF will have a larger per-share impact than in prior cycles; that creates a mechanical EPS tailwind even if segment EBIT is only modestly ahead. The pass-through structure also means the inflation/tariff debate is mostly a timing issue, not a margin-structure issue, which reduces downside from commodity volatility and shifts the focus to execution risk.

Consensus may still be underestimating how much of the story is deferred into 2027. If investors anchor on 2026 guidance, they may miss that the company is deliberately sacrificing near-term earnings to unlock network optimization in Europe and domestication in North America, with both assets likely to look far better after 2-4 quarters of stabilization. The main risk is that the market rerates the stock on the good 2025 print and fully discounts the 2026 bridge, leaving less upside until the first evidence of utilization improvement shows up mid-to-late year.

Key Decisions for Investors

• Long BALL on any post-earnings fade over the next 2-6 weeks; risk/reward favors buying weakness because 2026 is a transition year and the real upside catalyst is 2027 operating leverage, not the near-term guide.
• Pair trade: long BALL / short a higher-multiple consumer-packaging name with weaker FCF conversion over the next 3-6 months; BALL has better balance-sheet deleveraging and more visible buyback support, so relative performance should improve if rates stay stable.
• Use Jan-2027 call spreads on BALL to express the 2027 utilization inflection thesis; the upside is tied to Millersburg and Benepack ramp, while downside is limited to premium if the execution timeline slips.
• Watch for a 1H26 entry around any selloff tied to 'flat North America' headlines; that framing should be treated as trough-earnings, and the market could re-rate once back-half ramp evidence emerges.
• Avoid chasing after a strong move unless the stock resets to a more normal FCF yield; the current setup is more attractive as a medium-term compounder than as a momentum trade.